肾细胞癌组织学变异型与透明细胞癌各分期及治疗方式的比较
基于SEER登记(2001-2016)69,785例肾细胞癌患者,其中2,495例(3.6%)为组织学变异型。除黏液管状和梭形细胞外,变异型诊断时TNM分期均更晚;与G4透明细胞癌匹配后,集合管、肉瘤样、肾髓质和横纹肌样变异型的癌症特异性死亡风险更高。肉瘤样变异型行部分肾切除较根治性肾切除的生存更差。
要点
- 变异型组织学占肾细胞癌3.6%,其中肉瘤样占70.1%。
- 除黏液管状和梭形细胞外,变异型诊断时TNM分期均更晚。
- 集合管、肉瘤样、肾髓质和横纹肌样变异型癌症特异性死亡风险更高。
核心结论
- 变异型组织学肾细胞癌诊断时TNM分期普遍更晚,但黏液管状和梭形细胞除外。
- 集合管、肉瘤样、横纹肌样和肾髓质变异型的癌症特异性死亡风险高于透明细胞癌。
- 肉瘤样变异型行部分肾切除较根治性肾切除的癌症特异性死亡风险更高。
研究设计与样本
- 基于SEER登记(2001-2016)的回顾性队列研究。
- 共纳入69,785例肾细胞癌患者,其中变异型组织学2,495例(3.6%)。
- 采用累积发病率图、多因素Cox回归(匹配分期、分级等)及逆概率治疗加权分析。
主要发现
- 变异型组织学中肉瘤样占70.1%(1,748例),集合管占11.2%(280例),间叶型占7.6%(190例),神经内分泌型占3.8%(94例),肾髓质型占2.9%(72例),黏液管状和梭形细胞占2.5%(62例),横纹肌样占2.0%(49例)。
- 与G4透明细胞癌匹配后,集合管(多因素HR 1.6,p<0.01)、肉瘤样(HR 1.8,p<0.01)、肾髓质(HR 1.7,p=0.1)和横纹肌样(HR 1.5,p=0.1)变异型的癌症特异性死亡风险更高。
- 间叶型、神经内分泌型和黏液管状和梭形细胞变异型的癌症特异性死亡风险与透明细胞癌无差异。
- 肉瘤样变异型行部分肾切除较根治性肾切除的癌症特异性死亡风险更高(HR 1.2,p=0.02)。
临床怎么用
- 对变异型组织学肾细胞癌应警惕诊断时更晚的TNM分期。
- 集合管、肉瘤样、横纹肌样和肾髓质变异型需更密切的随访和积极治疗。
- 肉瘤样变异型选择部分肾切除需谨慎,可能增加癌症特异性死亡风险。
局限性
- 其他变异型组织学因样本量小无法评估肾切除方式的影响。
- 回顾性登记研究可能存在选择偏倚和未测量混杂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We evaluated stage at presentation and cancer specific mortality according to variant histology relative to clear cell renal cell carcinoma. MATERIALS AND METHODS: Within the Surveillance, Epidemiology, and End Results registry (2001-2016) we identified variant histology and clear cell renal cell carcinoma cases. Cumulative incidence plots, multivariate Cox regression models matched for stage, grade and other patient characteristics addressed cancer specific mortality. Subgroup analyses relied on inverse probability treatment weighting according to nephrectomy type. RESULTS: Of all 69,785 patients with renal cell carcinoma 2,495 harbored variant histology (3.6%). Of patients with variant histology 70.1% (1,748) harbored sarcomatoid vs 11.2% (280) collecting duct vs 7.6% (190) mesenchymal vs 3.8% (94) neuroendocrine vs 2.9% (72) renal medullary vs 2.5% (62) mucinous tubular and spindle cell, and 2.0% (49) rhabdoid tumors. All patients with variant histology exhibited more advanced TNM stage at diagnosis than clear cell renal cell carcinoma, except for mucinous tubular and spindle cell. After matching with G4 clear cell renal cell carcinoma, collecting duct (multivariate HR 1.6, p <0.01), sarcomatoid (HR 1.8, p <0.01), renal medullary (HR 1.7, p=0.1) and rhabdoid variant histology (HR 1.5, p=0.1) showed higher cancer specific mortality than clear cell renal cell carcinoma. No cancer specific mortality differences were recorded for mesenchymal, neuroendocrine and mucinous tubular and spindle cell variant histology. In nephrectomy subgroup higher cancer specific mortality was recorded after partial nephrectomy than radical nephrectomy in sarcomatoid variant histology after inverse probability treatment weighting and multivariate adjustment (HR 1.2, p=0.02). CONCLUSIONS: TNM stage at diagnosis is universally more advanced in patients with variant histology, except for mucinous tubular and spindle cell. Cancer specific mortality is higher in collecting duct, sarcomatoid, rhabdoid and renal medullary variant histology, but not in other variant histology. Partial nephrectomy is associated with worse survival in sarcomatoid variant histology but could not be assessed in other variant histology due to small sample size.
引用
- Deuker M, Stolzenbach F, Rosiello G, et al. Renal Cell Carcinoma: Comparison between Variant Histology and Clear Cell Carcinoma across All Stages and Treatment Modalities. J Urol. 2020. PMID: 32250728. doi:10.1097/JU.0000000000001063
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。